<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35167934</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>290</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lippia origanoides essential oil induces tocolytic effect in virgin rat uterus and inhibits writhing in a dysmenorrhea mouse model.</ArticleTitle>
        <Pagination>
          <StartPage>115099</StartPage>
          <MedlinePgn>115099</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2022.115099</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(22)00137-4</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">The species Lippia origanoides Kunth, popularly known as "salva-de-marajó", is used in Brazilian traditional "quilombola" communities to treat menstrual cramps and uterine inflammation.</AbstractText>
          <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">Evaluate the spasmolytic activity of Lippia origanoides essential oil (LOO) on experimental models of uterine conditions related to menstrual cramps and investigate its mechanism of action.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Virgin rat-isolated uterus was mounted in the organ bath apparatus to evaluate the spasmolytic effect of LOO on basal tonus and contractions induced by carbachol, KCl, or oxytocin. We used pharmacological agents to verify the relaxation mechanism of LOO. The evaluation of uterine contractility in virgin rats, after treatment with LOO for three consecutive days, was carried out by the construction of a concentration-response curve with oxytocin or carbachol. The primary dysmenorrhea animal model was replicated with an injection of estradiol cypionate in female mice for three consecutive days, followed by intraperitoneal application of oxytocin.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">LOO relaxed the rat uterus precontracted with 10<sup>-2</sup> IU/mL oxytocin (logEC<sub>50</sub> = 1.98 ± 0.07), 1 μM carbachol (logEC<sub>50</sub> = 1.42 ± 0.07) or 60 mM KCl (logEC<sub>50</sub> = 1.53 ± 0.05). It was also able relax uterus on spontaneous contractions (logEC<sub>50</sub> = 0.41 ± 0.05). Preincubation with glibenclamide, propranolol, phentolamine or L-NAME in contractions induced by carbachol did not alter significantly the relaxing effect of LOO. However, in the presence of 4-aminopyridine, CsCl or tetraethylammonium there was a reduction of LOO potency, whereas the blockers methylene blue, ODQ, aminophylline and heparin potentiated the LOO relaxing effect. Preincubation with LOO in a Ca<sup>2+</sup> free medium at concentrations of 27 μg/mL or 81 μg/mL reduced the contraction induced by carbachol. The administration of LOO for 3 days did not alter uterus contractility. The treatment with LOO at 30 or 100 mg/kg intraperitoneally, or 100 mg/kg orally, inhibited writhing in female mice. The association of LOO at 10 mg/kg with nifedipine or mefenamic acid potentiated writhing inhibition in mice.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The essential oil of L. origanoides has tocolytic activity in rat isolated uterus pre-contracted with KCl, oxytocin, or carbachol. This effect is possibly related to the opening of potassium channels (K<sub>ir</sub>, K<sub>V,</sub> and K<sub>Ca</sub>), cAMP increase, and diminution of intracellular Ca<sup>2+</sup>. This relaxant effect, probably, contributed to reduce the number of writhings in an animal model of dysmenorrhea being potentiated by nifedipine or mefenamic acid. Taken together, the results here presented indicate that this species has a pharmacological potential for the treatment of primary dysmenorrhea, supporting its use in folk medicine.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Macêdo</LastName>
            <ForeName>Cícero André Ferreira</ForeName>
            <Initials>CAF</Initials>
            <AffiliationInfo>
              <Affiliation>Pós-graduação em Biociênicas, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: andremacedo19@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paiva</LastName>
            <ForeName>Gabriela Olinda de</ForeName>
            <Initials>GO</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: gabsolinda@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menezes</LastName>
            <ForeName>Pedro Modesto Nascimento</ForeName>
            <Initials>PMN</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil; Rede Nordeste de Biotecnologia, Universidade Federal Rural de Pernambuco (UFRPE), Brazil. Electronic address: p.modesto89@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ribeiro</LastName>
            <ForeName>Tiago Feitosa</ForeName>
            <Initials>TF</Initials>
            <AffiliationInfo>
              <Affiliation>Rede Nordeste de Biotecnologia, Universidade Federal Rural de Pernambuco (UFRPE), Brazil. Electronic address: tiagofeitosaribeiro@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brito</LastName>
            <ForeName>Mariana Coelho</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: britomari31@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vilela</LastName>
            <ForeName>Deisy Azevedo Dourado</ForeName>
            <Initials>DAD</Initials>
            <AffiliationInfo>
              <Affiliation>Pós-graduação em Biociênicas, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: deisy.advilela@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duarte Filho</LastName>
            <ForeName>Luiz Antonio Miranda de Souza</ForeName>
            <Initials>LAMS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: duarte.luizfilho@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ribeiro</LastName>
            <ForeName>Fernanda Pires Rodrigues de Almeida</ForeName>
            <Initials>FPRA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: fernanda.pires@univasf.edu.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lucchese</LastName>
            <ForeName>Angélica Maria</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Química de Produtos Naturais e Bioativos, Departamento de Ciências Exatas, Universidade Estadual de Feira de Santana (UEFS), Brazil. Electronic address: angelica.lucchese@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lima</LastName>
            <ForeName>Julianeli Tolentino de</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: julianeli.lima@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Fabrício Souza</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Pós-graduação em Biociênicas, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil; Laboratório de Farmacologia Experimental, Colegiado de Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Brazil. Electronic address: fssilvafarma@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009822">Oils, Volatile</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015149">Tocolytic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>367589PJ2C</RegistryNumber>
          <NameOfSubstance UI="D008528">Mefenamic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>50-56-6</RegistryNumber>
          <NameOfSubstance UI="D010121">Oxytocin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>660YQ98I10</RegistryNumber>
          <NameOfSubstance UI="D011189">Potassium Chloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8Y164V895Y</RegistryNumber>
          <NameOfSubstance UI="D002217">Carbachol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I9ZF7L6G2L</RegistryNumber>
          <NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002217" MajorTopicYN="N">Carbachol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004412" MajorTopicYN="N">Dysmenorrhea</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032411" MajorTopicYN="Y">Lippia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008528" MajorTopicYN="N">Mefenamic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009543" MajorTopicYN="N">Nifedipine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009822" MajorTopicYN="N">Oils, Volatile</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010121" MajorTopicYN="N">Oxytocin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011189" MajorTopicYN="N">Potassium Chloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015149" MajorTopicYN="N">Tocolytic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014590" MajorTopicYN="N">Uterine Contraction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014599" MajorTopicYN="N">Uterus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dysmenorrhea</Keyword>
        <Keyword MajorTopicYN="N">Smooth muscle</Keyword>
        <Keyword MajorTopicYN="N">Spasmolytic effect</Keyword>
        <Keyword MajorTopicYN="N">Uterus</Keyword>
        <Keyword MajorTopicYN="N">Verbenaceae</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35167934</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2022.115099</ArticleId>
        <ArticleId IdType="pii">S0378-8741(22)00137-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
